Crossmark

Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response

Published Online: 2019-01-12

Published Print: 2019-12

Authors

Nelin, Leif D.

Potenziano, Jim L.
Funding

Funding for this research was provided by:

Mallinckrodt Pharmaceuticals
License Information

Text and Data Mining valid from 2019-01-12
More Information

Article History

Received: 21 December 2017

Accepted: 7 December 2018

First Online: 12 January 2019

Ethics approval and consent to participate

: The CINRGI study, the results of which were first published in 2000 (Clark RH, et al. N Engl J Med. 2000;342:469–74), was approved by the institutional review board at each study site, as listed in the Additional file InternalRef removed. Parents or guardians provided written informed consent.

: Not applicable.

: LDN declares that he has no competing interests. JLP is an employee of Mallinckrodt Pharmaceuticals.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current